Company profile

PledPharma is a Swedish specialty pharma company, which develops new treatments of life threatening diseases.

PledPharma currently runs two projects in clinical development phase II with the patented drug substance class, PLED-derivatives. The preventive effect of PLED-derivatives on adverse effects of chemotherapy in colorectal cancer is examined in one trial. Another trial investigates the ability of PLED-derivatives to reduce reperfusion injuries in myocardial infarction patients undergoing percutaneous coronary intervention (PCI).

PLED-derivatives protect the body’s normal cells against oxidative stress, which is a condition due to overproduction of oxygen-derived free radicals. PLED-derivatives have in previous pre-clinical trials been shown to protect against oxidative stress. Moreover, the PLED-derivative mangafodipir protected against the side effects of chemotherapy in colorectal cancer.

PledPharma (STO:PLED) is listed on NASDAQ OMX First North.

Our Mission

We develop improved treatments of life threatening diseases

Our Vision

To be the leading specialty pharma company, which develops medicines that protect healthy cells from oxidative stress during treatment of life threatening diseases

Our business model

We develop medicines in areas where there are huge medical needs. The projects are based upon patented and clinically available PLED-derivatives, and thereby combines huge medical need with strong likelihood of success. We are mid-term focusing on developing our projects to phase IIb, and then to out-license continued development and commercialization against milestone and royalty payments for the rights.